Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 9/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 4/20 | 0.41 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.41 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14887335 | 0.90 | BACE1 (0.42) | BACE1GAAKDM4EBACE2STIM1 | |
| SCHEMBL16019793 | 0.88 | DGAT1 (0.49) | SCN9ASTIM1ORAI1ALDH1A1 | |
| SCHEMBL16018223 | 0.88 | STIM1 (0.51) | BACE1SCN9ASTIM1ORAI1ALDH1A1 | |
| SCHEMBL14887577 | 0.86 | HSD17B10 (0.55) | SCN9AGAASTIM1ORAI1ALDH1A1 | |
| SCHEMBL16019786 | 0.83 | SCN9A (0.43) | SCN9AKDM4ESTIM1ORAI1ALDH1A1 | |
| SCHEMBL16019820 | 0.83 | KDM4E (0.54) | SCN9AKDM4ESTIM1ORAI1POLQ | |
| SCHEMBL14887767 | 0.81 | NAMPT (0.46) | SCN9ASTIM1ORAI1POLQ | |
| SCHEMBL16019777 | 0.81 | ALDH1A1 (0.53) | SCN9ASTIM1ORAI1ALDH1A1HSD17B10 | |
| SCHEMBL16017210 | 0.80 | MEN1 (0.50) | SCN9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL16017281 | 0.80 | STIM1 (0.44) | SCN9ASTIM1ORAI1ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. | 2014-09-11 | — | — | US | disclosed |
| WO-2013059666-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256771-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | BACE1 677/4885SCN9A 235/4885GAA 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.